Advertisement
UK markets closed
  • FTSE 100

    8,078.86
    +38.48 (+0.48%)
     
  • FTSE 250

    19,601.98
    -117.39 (-0.60%)
     
  • AIM

    753.12
    -1.57 (-0.21%)
     
  • GBP/EUR

    1.1653
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.2494
    +0.0031 (+0.25%)
     
  • Bitcoin GBP

    51,338.33
    -577.78 (-1.11%)
     
  • CMC Crypto 200

    1,386.98
    +4.41 (+0.32%)
     
  • S&P 500

    5,022.60
    -49.03 (-0.97%)
     
  • DOW

    37,928.00
    -532.92 (-1.39%)
     
  • CRUDE OIL

    82.50
    -0.31 (-0.37%)
     
  • GOLD FUTURES

    2,342.20
    +3.80 (+0.16%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • DAX

    17,917.28
    -171.42 (-0.95%)
     
  • CAC 40

    8,016.65
    -75.21 (-0.93%)
     

Pfizer COVID vaccine safe for younger kids -data

Welcome news for anxious parents eager to have their kids vaccinated against COVID-19…

Pfizer and BioNTech said Monday that a lower dose of their COVID-19 vaccine induces a robust immune response in 5 to 11 year olds, and they plan to ask for authorization – from the FDA and other regulators - as soon as possible.

Clinical trials showed the Pfizer vaccine was well-tolerated, and generated an immune response in 5 to 11 year-olds, as it had in the older age range. The dose for younger kids was one-third the size.

The companies said the safety profile was also generally comparable.

Top U.S. health officials believe regulators could make a decision on whether a lower dose shot is safe and effective for this age group within three weeks of the companies submitting a request for authorization, according to sources.

ADVERTISEMENT

A rapid authorization in the U.S. could help stem a potential surge of coronavirus cases in the fall, with schools open across the country.

Pediatric cases have risen sharply in recent months - as have hospitalizations - due to the highly contagious Delta variant.